Systematic review of 25 RCTs in localised renal cell carcinoma (13 trials, 9594 patients, meta-analysed): trial-level DFS correlated strongly with overall survival (r 0.75; R² 0.57); a DFS HR <0.914 predicted an OS benefit, supporting DFS as a surrogate end point.
Meta-analysisn = 9,594
Martinez et al. Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis